Concepedia

Caroline Clairmont

CC

Statistics

Publications

16

Citations

1.5K

H-Index

15

Active since

1990

Affiliations

Vion Pharmaceuticals (United States)(Current)

Yale University

Arizona Research Center

University of Massachusetts Chan Medical School

Caroline Clairmont is an author at Vion Pharmaceuticals (United States) specializing in medicine, molecular biology, and natural sciences.

Top concepts

Publications per year

1990–2005

16

Publications

16

Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of<i>Salmonella typhimurium</i>

Caroline Clairmont, K. C. Lee, Jeremy A. Pike et al. · The Journal of Infectious Diseases · 2000 · 334 citations · Full text

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

John Nemunaitis, Casey Cunningham, Neil Senzer et al. · Cancer Gene Therapy · 2003 · 332 citations

, , +10

Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion

Scott Wadler, Della Makower, Caroline Clairmont et al. · Journal of Clinical Oncology · 2004 · 145 citations

Translocation of ATP into the lumen of rough endoplasmic reticulum-derived vesicles and its binding to luminal proteins including BiP (GRP 78) and GRP 94.

Caroline Clairmont, Antonio De Maio, C B Hirschberg · Journal of Biological Chemistry · 1992 · 135 citations · Full text

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

John R. Murren, Manuel Modiano, Caroline Clairmont et al. · PubMed · 2003 · 107 citations

1–5 of 16